Traditional MedicareCoverageMedium impact
MolDX: Molecular Assays for the Diagnosis of Cutaneous Melanoma
Medicare/CMS - LCD·Dermatology, Pathology, Oncology·Local Coverage Determination
Effective date
Apr 16, 2026
We identified it
Jun 17, 2026
Summary
This is a Local Coverage Determination for molecular assays used in diagnosing cutaneous melanoma, effective April 16, 2026. The policy establishes coverage criteria for molecular diagnostic tests specific to skin melanoma under Medicare Part A and Part B.
Action Required
By April 16, 2026: Billing team must review the full LCD policy L39389 to understand coverage criteria for molecular melanoma diagnostic assays. Update billing procedures to ensure molecular assays for cutaneous melanoma diagnosis meet Medicare coverage requirements. Coordinate with dermatology and pathology departments to ensure proper documentation and coding compliance.